Green Planet Bioengineering Co. Ltd.

As of June 30, 2026, Green Planet Bioengineering Co. Ltd. carries a market capitalization of 260,083.23, placing it among publicly traded companies globally. Its enterprise value stands at 260,083.23, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Green Planet Bioengineering Co. Ltd. has 20.01M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Green Planet Bioengineering Co. Ltd. maintains a current ratio of - -, meaning it holds the short-term assets needed to cover near-term liabilities.

As of the close on October 22, 2026, Green Planet Bioengineering Co. Ltd.'s stock has declined approximately 75.00% over the past 52 weeks. The 50-day moving average sits at 0.33, while the 200-day moving average is 1.18.

Over the twelve months ended June 30, 2026, Green Planet Bioengineering Co. Ltd. generated - - in revenue and converted that into -41,746.00 in net income, yielding earnings per share of 0.00. EBITDA reached -41,596.00, while operating income came in at -41,596.00.

These figures are as of June 30, 2026. Total book value stands at -517,825.00, with working capital of -517,825.00 providing operational flexibility.

Green Planet Bioengineering Co. Ltd. produced -52,896.00 in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -20.34: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -20.34, meaning Green Planet Bioengineering Co. Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.